Ubiquitin ligase c-Cbl is involved in tamoxifen-induced apoptosis of MCF-7 cells by downregulating the survival signals

References

• Parton M, Dowsett M, Smith I. Studies of apoptosis in breast cancer. BMJ 2001;322:1528–32.
   Google Scholar
• Otto A, Paddenberg R, Schubert S, Mannhertz H. Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin. J Cancer Res Clin Oncol 1996;22:603–12.
   Google Scholar
• Perry R, Kang Y, Greaves B. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 1995;2: 238–45.
   PubMed Web of Science ®Google Scholar
• Hui AM, Zhang W, Chen W, Xi D, Purow B, Friedman GC, . Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res 2004;64:9115–23.
   PubMed Web of Science ®Google Scholar
• Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001;6:469–77.
   PubMed Web of Science ®Google Scholar
• Ferlini C, Scambia G, Marone M, Distefano M, Gaggini C, Ferrandina G, . Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines. Br J Cancer 1999;79:257–63.
   PubMed Web of Science ®Google Scholar
• Reissig D, Clement J, Sanger J, Berndt A, Kosmehl H, Bohmer FD. Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue. J Cancer Res Clin Oncol 2001;127: 226–30.
   PubMed Web of Science ®Google Scholar
• Hiscox S, Morgan L, Green T, Nicholson RI. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocrine-Related Cancer 2006;13(Suppl 1): S53–S59.
   Google Scholar
• Planas-Silva MD, Hamilton KN. Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins. Cancer Chemother Pharmacol 2007;60:535–43.
   PubMedGoogle Scholar
• Ghayad SE, Vendrell JA, Larbi SB, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 2010; 126:545–62.
   PubMed Web of Science ®Google Scholar
• Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci USA 2002;99:14783–8.
   PubMed Web of Science ®Google Scholar
• Yokouchi M, Kondo T, Sanjay A, Houghton A, Yoshimura A, Komiya S, . Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins. J Bio Chem 2001;276:35185–93.
   PubMed Web of Science ®Google Scholar
• Rao N, Dodge I, Band H. The Cbl family of ubiquitin ligases: Critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol 2002;71:753–63.
   PubMed Web of Science ®Google Scholar
• Fang D, Wang HY, Fang N, Altman Y, Elly C, Liu YC. Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells. J Biol Chem 2001; 276:4872–8.
   PubMed Web of Science ®Google Scholar
• Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, . Mutations of E3 ubiquitin ligase Cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009;27:6109–16.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Qu X, Hu X, Yang X, Hou K, Teng Y, . Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J Pathol 2009;218:248–55.
   Google Scholar
• Qu X, Zhang Y, Li Y, Hu X, Xu Y, Xu L, . Ubiquitin ligase Cbl-b sensitizes leukemia and gastric cancer cells to anthracyclines by activating the mitochondrial pathway and modulating Akt and ERK survival signals. FEBS Letters 2009;583:2255–62.
   Google Scholar
• Murphy, MA, Schnall, RG, Venter, DJ, Barnett L, Bertoncello I, Thien, CB, . Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol Cell Biol 1998;18:4872–82.
   PubMed Web of Science ®Google Scholar
• Kyo S, Sada K, Qu X, Maeno K, Miah SM, Kawauchi-Kamata K, . Negative regulation of Lyn protein-tyrosine kinase by c-Cbl ubiquitin-protein ligase in FcεRI-mediated mast cell activation. Genes Cells 2003;8:825–36.
   PubMedGoogle Scholar
• Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002;295:2465–8.
   PubMed Web of Science ®Google Scholar
• Herynk MH, Beyer AR, Cui Y, Weiss H, Anderson E, Green TP, . Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptorpositive human breast cancer cells. Mol Cancer Ther 2006;5: 3023–31.
   PubMed Web of Science ®Google Scholar
• Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707–17.
   PubMed Web of Science ®Google Scholar
• Tian F, Wu H, Li Z, Wang N, Huang J, Li C, . Activated PKCα/ERK1/2 signaling inhibits tamoxifen-induced apoptosis in C6 cells. Cancer Invest 2009;27:802–8.
   PubMed Web of Science ®Google Scholar
• Sanjay A, Horne WC, Baron R. The Cbl family: Ubiquitin ligases regulating signaling by tyrosine kinases. Sci STKE 2001;2001:pe40.
   Google Scholar
• Miyake S, Mullane-Robinson KP, Lill NL, Douillard P, Band H. Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain. J Biol Chem 1999;274:16619–28.
   PubMed Web of Science ®Google Scholar
• Sargin B, Choudhary C, Crosetto N, Schmidt MH, Grundler R, Rensinghoff M, . Flt3-dependent transformation by inactivating c-Cbl mutations in AML. Blood 2007;110: 1004–12.
   PubMed Web of Science ®Google Scholar